New combo attack on tough leukemia
NCT ID NCT05024552
Summary
This early-phase study is testing the safety and best dose of a two-drug combination (Vyxeos and gilteritinib) for adults with a specific type of acute myeloid leukemia (AML) that has a FLT3 mutation and has returned or not responded to prior treatment. The goal is to see if this combination can help control the cancer and lead to remission, potentially followed by a stem cell transplant or ongoing maintenance therapy. The study will enroll about 22 participants to find the safest dose and gather initial information on how well the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA WITH FLT3/ITD MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.